Cardiac

Acute MI     z Post myocardial infarction akinetic myocardium

Heart failure     Dilated  cardiomyopathy

Non revascularizable ischemic myocardium

The myocardium does indeed have a limited regenerative capacity Patients with whatever the aetilogu ultimately have a significantly decreased left ventricular function with ejection fraction irreversible loss of tissue due to the fact that the infarcted tissue is not viable. research  activity into the promise of stem cell therapy for end-stage heart disease.

Stem cells from adipose tissue offer a novel therapy for patients with SVF injected into areas of low perfusion or scars in the cardiac tissue may become populated with angiogenic stem cells, improving blood supply in the area and reducing myocardial scar size

Stem cells from adipose tissue offer a novel therapy for patients having areas of low perfusion or scars in the cardiac tissue, improving blood supply in the area and reducing myocardial scar size myocardial infarction and dilated cardiomyopathy  significantly improves left ventricular cardiac function and decreases mortality The benefits are postulated to come from their influence on neovascularization of the ischemic tissue and their protection of resident cells  The paracrine and secretion of  various angiogenic  and survival growth factors further enhance the recovery of injured myocardium.

How it is done-

The goal is to transplantat the cells in infracted .weak /damaged  myocardium directly or indirectly .

In Acute MI  it is done At 3 to 7 days of Post MI after successful  PCI and stent implantauion.

The possible routes are :

Intracoronary Transplantation

Intramyocardially thru catheter

or direct during open heart  surgery

Intracoronary Transplantation :cells can be administered into coronary artery just like a dye as in routine angiographic procedures . the cells get distributed into whole of myocardium thru branches of coronary artery

Intramyocardially thru catheter

The cells can also be administered  intra-myocardially into the targeted treatment region using the special catheter delivery system under fluoroscopic guidance.  Multiple injections of 0.25ccs each were delivered into the myocardium

What to expect  

After treatment  80 %patients  reach close to Six-minute walk test (6MWT) of >400 meters

70 % patients achieve Minnesota Living With Heart Failure (MLWHF) score of <20

Myocardial wall thickness of  improves to > 10  mm in the  injected site in 60 %

Left ventricular ejection fraction (LVEF)  reaches mean of 45  at 6 months in 74 % of patients  from a  mean of 30 before treatment

80 %Reach (NYHA) Class II  from pre treatment IV

Significant improvement in B-type natriuretic peptide (BNP) or NT pro-BNPin 50% of patients.

Percent wall thickness increased from 25 % to 50 % over 12 months